Janssen completes two studies confirming positive efficacy of XARELTO (rivaroxaban) in treating bloo
Janssen Pharmaceuticals and its development partner, Bayer, announced results of two new real-world studies confirming the positive benefit-risk profile of XARELTO (rivaroxaban) in treating venous thromboembolism (VTE), or blood clots, and reducing the risk of recurrence.
